首页|SARS-CoV-2 infection and the antiviral innate immune response
SARS-CoV-2 infection and the antiviral innate immune response
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak began in December 2019, causing the illness known as the novel coronavirus disease 2019 (COVID-19). The virus spread rapidly worldwide to become a global public health emergency. As of November 15, 2020, more than 53 million confirmed cases and over 1 million deaths worldwide have been reported (World Health Organization, 2020). The SARS-CoV-2 genome was sequenced and studies are ongoing to further understand the epidemiology, clinical manifestations, eti-ological structure, cellular receptor angio-tensin II converting enzyme (ACE2), and intracellular replication process of the virus. Currently, thousands of clinical trials related to SARS-CoV-2 are underway (https://clinicaltrials.gov/).
Hui Yang、Yingying Lyu、Fajian Hou
展开 >
Department of Neurosurgery, Huashan Hospital, Institute for Translational Brain Research, MOE
NSTL
